Silence Therapeutics Files Registration Statement For ADS Listing
Silence Therapeutics Files Registration Statement For ADS Listing
Read moreSilence Therapeutics Files Registration Statement For ADS Listing
Read moreSilence Therapeutics To Develop Two More RNA Assets For Mallinckrodt
Read more(Sharecast News) - RNA therapeutics developer Silence Therapeutics said on Tuesday that it had continued to make "exceptional progress" in securing additional high-value partnerships and advancing its proprietary pipeline year-to-date.
Read moreUK DIRECTOR DEALINGS SUMMARY: Moya Greene Buys GBP50,000 In easyJet
Read more(Sharecast News) - Silence Therapeutics revealed on Tuesday that chief financial officer Rob Quinn had offloaded of 89,054 ordinary shares in the AIM-listed biotechnology group.
Read moreUK DIRECTOR DEALINGS SUMMARY: Silence CFO Sells GBP360,000 Worth
Read moreSilence Therapeutics 2019 Loss Widens On Higher Research Costs
Read moreUK TRADING UPDATE SUMMARY: Naked Wines, Distil Get Bar-Closure Boost
Read moreUK Earnings, Trading Statements Calendar - Next 7 Days
Read moreUK EXECUTIVE CHANGE SUMMARY: Iofina Recruits Former Oklahoma Governor
Read moreUK WINNERS & LOSERS SUMMARY: Rentokil Falls After Scrapping Dividend
Read moreSilence Therapeutics Agrees Strategic Collaboration With AstraZeneca
Read moreUK BROKER RATINGS SUMMARY: Peel Hunt Cuts Ashtead And Raises DCC
Read more(Sharecast News) - Serious disease therapeutics developer Silence Therapeutics updated the market on the year ended 31 December on Tuesday, reporting that it has entered into a technology evaluation agreement with Takeda to explore the potential of using its platform to generate siRNA molecules against a novel, undisclosed target discovered by Takeda.
Read moreSilence Therapeutics Plans New US Subsidiary; Inks Deal With Takeda
Read more